INSM INSMED Inc stock chart & analysis
Conviction 47HealthcareScan · Fri, Nov 6, 2026INSMED Inc (INSM) closed at $114.41 (+5.19%) on Nov 6, 2026. Price is above its 50-day and below its 200-day moving average. RSI(14) 61, RS Rating 18, -46.2% from its 52-week high, -34.3% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why INSM moved
From the StockSetups movers recaps that covered INSM, newest first. A recap states what was known that day.
- Close+33.9%
Insmed reported Q2 2026 financial results that beat revenue estimates, even as the company posted a net loss, according to Yahoo Finance coverage on August 6. The revenue beat for a commercial-stage rare-disease biotech signals that its lead asset's commercial trajectory is stronger than consensus expected.
Top Stock Movers Today — August 6, 2026: Why WYHG, IOVA, HNST, ASPN & INSM Surged →
Financials as of Wed, Sep 30, 2026 · quarterly.
INSM technical analysis
Trend
INSM's moving averages are mixed — no clean uptrend or downtrend. It closed 2.9% above the 50-day ($111.21) and 7.8% below the 200-day ($124.15). ADX(14) at 33 points to a strong, established trend. It meets 1 of 8 trend-template criteria.
Momentum
RSI(14) is 61, in the bullish half of its range. MACD crossed above its signal line 8 sessions ago. Its RS Rating of 18 puts its weighted 12-month performance ahead of about 18% of the US market.
Volume and volatility
Volume on the latest session ran 2.1× its 20-day average. It trades about $419.8M a day on average. ATR(14) is $5.11, 4.5% of price — its typical daily range. On-balance volume is trending up.
Key levels
The chart pattern's support is $94.19 and its resistance $125.15. The 52-week range is $90.39 to $212.75; price is 46.2% below the high and 26.6% above the low. The VWAP anchored at the 52-week high is $128.79, above price.
Performance
INSM returned +1.6% (1 week), +13.9% (1 month), -15.1% (3 months), +12.9% (6 months), -38.8% (1 year), -34.3% (year to date).
About INSMED Inc
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Pharmaceutical Preparations · Listed 2000 · 1,664 employees
Recent news
- Insmed to Present at November and December 2026 Investor ConferencesPR Newswire · Wed, Nov 4, 2026
Congress activity
Disclosed STOCK Act trades in INSM · 6 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Josh Gottheimer house · D · NJ · traded 2026-06-10 | Sell | $1K–$15K | 2026-06-10 | 2026-07-07 | |
 Gilbert Cisneros house · D · CA · traded 2025-09-22 | Sell | $1K–$15K | 2025-09-22 | 2025-10-10 | |
Gilbert Cisneros house · D · CA · traded 2025-08-08 | Sell | $1K–$15K | 2025-08-08 | 2025-09-12 | |
Gilbert Cisneros house · D · CA · traded 2025-07-07 | Sell | $1K–$15K | 2025-07-07 | 2025-08-14 | |
Josh Gottheimer house · D · NJ · traded 2025-06-16 | Buy | $1K–$15K | 2025-06-16 | 2025-07-16 | |
Josh Gottheimer house · D · NJ · traded 2025-04-09 | Sell | $1K–$15K | 2025-04-09 | 2025-05-14 |
Insider activity
SEC Form 4 transactions in INSM · open-market 3 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Brennan David R Director · Common Stock · 2026-09-09 | Sell | 25K | $3.1M | 2026-09-09 | 2026-09-11 |
SHAROKY MELVIN MD Director · Common Stock · 2026-08-17 | Sell | 5K | $638K | 2026-08-17 | 2026-08-19 |
Adsett Roger Chief Operating Officer · Common Stock · 2026-08-10 | Exercise | 82.28K | $1.1M | 2026-08-10 | 2026-08-12 |
Adsett Roger Chief Operating Officer · Common Stock · 2026-08-10 | Exercise | 76.6K | $1.3M | 2026-08-10 | 2026-08-12 |
Adsett Roger Chief Operating Officer · Common Stock · 2026-08-10 | Exercise | 80.97K | $2.5M | 2026-08-10 | 2026-08-12 |
Adsett Roger Chief Operating Officer · Common Stock · 2026-08-10 | Sell | 239.85K | $32M | 2026-08-10 | 2026-08-12 |
Adsett Roger Chief Operating Officer · Stock Option (right to buy) · 2026-08-10 | Exercise | 82.28K | — | 2026-08-10 | 2026-08-12 |
Adsett Roger Chief Operating Officer · Stock Option (right to buy) · 2026-08-10 | Exercise | 76.6K | — | 2026-08-10 | 2026-08-12 |
Adsett Roger Chief Operating Officer · Stock Option (right to buy) · 2026-08-10 | Exercise | 80.97K | — | 2026-08-10 | 2026-08-12 |
Flammer Martina M.D. Chief Medical Officer · Stock Option (right to buy) · 2026-08-06 | Exercise | 18.28K | — | 2026-08-06 | 2026-08-07 |
SEC filings
EDGAR filings in INSM · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.